OptMed, Inc. is a privately held medical device company focused on developing, manufacturing, and commercializing a portfolio of skin protectants and surgical adhesives—designed for both topical and internal use—built on its proprietary methylidene malonate chemistry platform.
OptMed, Inc. skin-protectant products are commercially available under the EpiPly® (US) and BlauProtect® (EU) brands.
BondEase® Topical Skin Adhesive, OptMed’s first clinical indication, has received FDA 510(k) clearance for marketing. The FDA has also granted 510(k) marketing clearance to TearRepair® as a skin protectant.
Martin Sands serves as Co-Chairman of OptMed’s Board of Directors. A veteran investor and co-founder of Sands Brothers Asset Management, Sands brings decades of experience in biotechnology, medical technology, and life-science investing. His background includes venture capital, private equity, and hedge-fund management, with a long track record of supporting emerging healthcare innovations. At OptMed, he has played both a strategic and governance role, helping guide the company’s growth, product development, and international partnerships, including past investment-related initiatives highlighted in industry publications.
